Batoprazine

Batoprazine

SCHEMBL766463

O=c1ccc2cccc(N3CCNCC3)c2o1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.53
HTR2A P28223 2/20 0.53
HTR3E A5X5Y0 1/20 0.53
HTR3B O95264 1/20 0.53
CYP1A2 P05177 1/20 0.53
HTR1A P08908 1/20 0.53
CYP2D6 P10635 1/20 0.53
NCF1 P14598 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
HTR1D P28221 1/20 0.53
HTR1B P28222 1/20 0.53
HTR7 P34969 1/20 0.53
MTOR P42345 1/20 0.53
HTR3A P46098 1/20 0.53
HTR6 P50406 1/20 0.53
HTR3D Q70Z44 1/20 0.53
HTR3C Q8WXA8 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SIGMAR1 Q99720 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9228925 0.78 HTR5A (0.52) HTR5AHTR2AHTR3EHTR3BCYP1A2
SCHEMBL9226988 0.78 ADRB1 (0.46) HTR2AHTR3EHTR3BCYP1A2HTR1A
SCHEMBL9230056 0.78 HTR6 (0.41) HTR1AHTR3AHTR6KDM4EALDH1A1
SCHEMBL2545146 0.78 HTR3E (0.56) HTR5AHTR2AHTR3EHTR3BCYP1A2
SCHEMBL9229724 0.77 HTR6 (0.48) HTR5AHTR2AHTR3EHTR3BCYP1A2
SCHEMBL930509 0.77 HTR5A (0.48) HTR5AHTR2AHTR3EHTR3BCYP1A2
SCHEMBL9229904 0.77 ADRB1 (0.51) HTR5AHTR2AHTR3EHTR3BCYP1A2
Hydrochloric Acid SCHEMBL9225164 0.77 HTR5A (0.51) HTR5AHTR2AHTR3EHTR3BCYP1A2
Hydrochloric Acid SCHEMBL9224129 0.77 ADRB1 (0.45) HTR2AHTR3EHTR3BCYP1A2HTR1A
Hydrochloric Acid SCHEMBL10523385 0.76 KDM4E (0.57) KDM4EALDH1A1LMNAHPGDPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190091164-A1 Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same PFIZER INC. (US) 2019-03-28 US claimed
CN-108348506-A Include the therapeutic nanoparticle and its preparation and application of therapeutic agent 辉瑞公司 2018-07-31 CN claimed
EP-3337516-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME Pfizer Inc (US) 2018-06-27 EP claimed
WO-2017034991-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME PFIZER INC. (US) 2017-03-02 WO claimed
US-20170049709-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME PFIZER INC. 2017-02-23 US claimed
CN-105636438-A Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof CHEN JIANHONG 2016-06-01 CN claimed
EP-2983473-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS Mountain Llc (US) 2016-02-17 EP claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US claimed
US-20140350064-A1 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS MOUNTAIN LLC 2014-11-27 US claimed
WO-2014144130-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS MOUNTAIN LLC (US) 2014-09-18 WO claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 CN claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 US claimed
US-20120183600-A1 NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS CHEN CHIEN-HUNG (US) 2012-07-19 US claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
JP-7188207-A None JP disclosed
EP-0490772-A1 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1992-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA HTR5A 1652/4885HTR2A 2235/4885HTR3E 1997/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA HTR5A 1652/4885HTR2A 2235/4885HTR3E 1997/4885
US-20190091164-A1 Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same CTSA, GAA, EEA1 HTR5A 4777/4885HTR2A 4616/4885HTR3E 4043/4885
US-20170049709-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME CTSA, GAA, EEA1 HTR5A 4777/4885HTR2A 4616/4885HTR3E 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.